Objective. The aim of this study was to test the hypothesis that statin therapy confers benefit on the microvasculature, including improving endothelial function, in patients with SSc.
Introduction
The pathogenesis of SSc is complex and not completely understood but results from a complex interplay of vasculopathy, excessive fibrosis and activation of the immune system [1] . The vascular changes affect the microvasculature predominantly: both structural and functional abnormalities are well recognized [2, 3] . As yet there is no known effective disease-modifying treatment.
In recent years, there has been considerable interest in the hypothesis that statins might have a favourable influence on the SSc disease process [4] . This is because statins have a variety of effects, in addition to lowering lipid levels, including: increased production of the vasodilator nitric oxide, inhibition (in fibrotic disorders) of overproduction of matrix components, down-regulation of expression of several adhesion molecules and inhibition of the migration of lymphocytes to areas of inflammation [4] . These actions suggest that statins might modify all three aspects of the SSc disease process: the vasculopathy, the fibrosis and the immune dysfunction.
Several investigators have examined the effects of statins on different aspects of the SSc disease process. Kuwana et al. [5] , in an open study of 14 patients with SSc, reported that 12 weeks treatment with atorvastatin 10 mg/day increased the number of bone marrow-derived circulating endothelial cell precursors (which are reduced in SSc and required for vasculogenesis) and reduced circulating levels of two angiogenic factors (vascular endothelial growth factor and basic fibroblast growth factor) and of two markers of endothelial cell activation/ injury (soluble vascular cell adhesion molecule 1 and soluble E-selectin). In a study of 18 patients with SSc, 9 of whom received statin therapy [6] , 8 weeks treatment with pravastatin 10 mg/day was associated with a reduction in levels of von Willebrand factor (vWF), probably the gold standard plasma marker of endothelial cell activation/ injury [7] . Louneva et al. [8] conducted a series of experiments on fibroblast cultures and found that simvastatin inhibited COL1A1 expression, at the transcriptional level, in SSc and normal fibroblasts, thus demonstrating that statins might have a beneficial effect on the fibrosis of SSc. Very recently, Abou-Raya et al. [9, 10] reported improvements in both clinical and laboratory measurements in patients with SSc treated with atorvastatin.
Against this background of a number of reports suggesting favourable effects on both the vascular and fibrotic aspects of SSc, our aim was to test the hypothesis that statin therapy confers benefit on the microvasculature, including improving microvascular endothelial function, in patients with SSc. Specific objectives were to investigate whether 8 weeks treatment with atorvastatin favourably influenced microvascular endothelial-dependent and endothelial-independent vasodilation, nail-fold capillary structure, patient opinion of RP and circulating levels of vWF and of high-sensitivity CRP.
Patients and methods

Patients
Patients with SSc, aged between 18 and 75 years, were recruited into the study. Patients were excluded from the study if they were pregnant, breastfeeding or if they had any contraindications to statin therapy (hypersensitivity, active liver disease, unexplained persistent elevations of serum transaminases, elevated creatine kinase and history of heavy alcohol consumption). They were also excluded if they were currently, or had been, taking statin therapy in the 3 months before enrolling into the study. In addition, patients who were identified at their screening visit as having an elevated cardiovascular disease risk (>20% over the next 10 years) [11] , were not included, and their general practitioners contacted with the recommendation that their cardiovascular risk be further assessed/treated. The study was approved by Salford and Trafford Research Ethics Committee. All patients signed informed consent.
Study design
This was a randomized, parallel group, double-blind study, with assessments (after screening) at baseline (Week 0), 4 and 8 weeks. The screening visit included checking of the fasting cholesterol and of the study exclusion criteria including contraindications to statin therapy. Eligible patients were randomly assigned to receive treatment with either atorvastatin 20 mg/day or matching placebo therapy for 8 weeks. Patients were asked to abstain from smoking and caffeine-containing drinks on each of the 3 study days, and were asked to fast for the 8-week visit as well as for the screening visit (for checking of fasting cholesterol). Patients continued on their other medications throughout the 8-week study period, with instructions wherever possible not to make changes in vasoactive therapies (e.g. calcium channel blockers) throughout the study period. Safety monitoring (liver function and creatine kinase) was performed at 8 weeks.
Outcome measures. Endothelial-dependent vasodilation at 8 weeks, assessed by response to iontophoresis with acetylcholine chloride (ACh), and endotheliumindependent vasodilation, assessed by response to iontophoresis with sodium nitroprusside (NaNP), were measured by laser Doppler imaging as previously described [12] . Microvascular structure was assessed by videocapillaroscopy [13, 14] . Other outcomes were patient opinion of RP [assessed by visual analogue scale (VAS)], vWF and high-sensitivity CRP. These outcome measures were all performed or checked at baseline, 4 and 8 weeks.
Procedures
Patients were acclimatized for 20 min at a room temperature of 23 C prior to iontophoresis and nail-fold capillaroscopy.
Iontophoresis-microvascular function. The iontophoresis/ laser Doppler imaging protocol was almost exactly as previously described [12] , the only difference being that the laser Doppler scanning time for each scan was 19 s rather than 17 s. Briefly, two iontophoresis chambers, each with a platinum wire electrode, were attached to two adjacent fingers of the left hand. One chamber, attached to the positive electrode, was filled with a solution of 1% ACh and the other, attached to the negative electrode, with 1% NaNP. After the measurement of baseline blood flow [using a scanning 633-nm red laser Doppler imager (Moor LDI-VR scanner, Moor Instruments, Axminster, Devon, UK)], iontophoresis (both chambers simultaneously) was commenced at 30 mA for 120 s. At the commencement of the iontophoresis the laser Doppler imager initiated recording of 25 serial scans (19 s duration www.rheumatology.oxfordjournals.org each, 1 s between scans) measuring blood flow at the areas of iontophoresis. From each set of scans (ACh and NaNP for each patient) the following measurements were taken: area under the curve (AUC), peak blood flow and mean blood flow.
Nail-fold capillaroscopy-microvascular structure. The ring finger of the patient's non-dominant hand was examined. A panoramic, high magnification (Â300) image of the nailfold was obtained as previously described [13] . Images were manually marked at each capillary apex to allow automated analysis [14] of intercapillary distance, tortuosity (curliness), derangement (variation in dominant direction of capillaries) and capillary width.
Other outcome measures. Patient opinion of RP was measured by VAS. vWF was assayed by a standard ELISA techniques (Dako-Cytomation, Ely, Cambs, UK) [15] . High-sensitivity CRP was assayed by latex-enhanced immunoturbidimetric assay (Olympus UK, Watford, UK), with all samples assayed in a single batch. It is well established that circulating levels of vWF are elevated in SSc [16] , and more recently we have shown that high-sensitivity CRP is also raised, particularly in those patients with internal organ involvement [17] .
Statistical methods
Sample size. It was estimated that inclusion of 16 patients in each group (32 patients in total) would have 80% power at the 5% significance level to detect a difference of 1 S.D. To allow for drop-out, 18 patients were enrolled in each group.
Patients were assigned in a random manner in groups of four. A computer-generated sequence was prepared by the company providing the study capsules, which were then shipped in serial-numbered, blinded packaging to ensure allocation concealment.
Iontophoresis outcomes were assessed both with and without adjustment for initial value. Adjusted AUC was the area between the curve and the initial level, adjusted 'peak' was the height of the curve above the initial flux level and adjusted 'mean' was the mean difference from the initial level. The primary outcome was the unadjusted AUC for endothelial-dependent vasodilation at 8 weeks. Other outcomes were considered as secondary.
Group differences were assessed by linear regression (analysis of covariance) controlling for baseline values of the corresponding measure, and presented as estimated mean difference (95% CI).
Results
Patient characteristics and progression through the study Thirty-six patients with SSc were recruited from Salford Royal Hospital. The clinical features of those randomly assigned to the two treatment groups are summarized in Table 1 . Patients were subdivided into those with limited cutaneous and diffuse cutaneous disease on the basis of the extent of skin involvement as defined by LeRoy et al. [18] . In limited cutaneous disease, skin involvement is confined to distal to the elbows, knees and neck. In diffuse disease, proximal limb and/or trunk are involved.
Patient progression through the study is shown in Fig. 1 . There were two withdrawals from the atorvastatin group and three from the placebo group, resulting in 16 patients on atorvastatin and 15 on placebo, completing the 8-week treatment period. The two atorvastatin withdrawals were because: one patient (at baseline) found the tablets too large to swallow and one patient (at 4 weeks) developed finger-tip lesions and periungual erythema and it was questioned whether these might be side effects of treatment. The three placebo withdrawals were all due to gastrointestinal adverse effects: one subject at Week 2 and two at Week 5. None of the patients developed any abnormalities in liver function or creatine kinase. In three subjects (one atorvastatin, two placebo), results were incomplete because of failure to achieve a watertight seal between the finger and the iontophoresis chamber, resulting in vasodilator leakage. Therefore, complete results were available in 15 atorvastatin-and 13 placebotreated patients.
Microvascular structure and function
Results are shown in Tables 2 and 3 and in Fig. 2 , with estimated group differences at Week 8 (adjusted for corresponding baseline/Week 0 value) shown in Table 4 . The key finding was that there were no statistically significant differences between the atorvastatin and placebo groups in either ACh (endothelium dependent) or NaNP (endothelial independent) AUC, peak blood flow or mean blood flow either without (Table 2 , Fig. 2 ) or with adjustment for baseline flux (data not shown for adjusted values). Nor were there any significant differences between groups in any of the capillaroscopic measurements (Tables 3 and 4) .
Other outcome measures
There were no significant differences between groups in patient opinion of RP, vWF or high-sensitivity CRP (Tables 3 and 4) . As anticipated, cholesterol fell in the atorvastatin group (Table 4 ). This suggests that the treatment was taken and that the study had adequate power to detect the well-recognized effect of statin on cholesterol.
Discussion
Atorvastatin 20 mg/day, given for 8 weeks, was not associated with measurable changes in microvascular structure or function, nor was it associated with any improvement in symptoms of RP or fall in vWF factor or in high-sensitivity CRP. As anticipated, circulating levels of cholesterol fell on treatment.
There are several reasons for this lack of effect, but a key point is that most patients had well-established vascular disease, with a median duration of RP of 18 years and of SSc disease duration of 9 years. Only two of the active treatment group who completed follow-up were within 3 years of SSc diagnosis. While there were too few for formal assessment, these two were among the highest 'responses' in the primary outcome. It is possible, therefore, that most patients had irreversible structural microvascular disease that was unlikely to respond to statin therapy. Also, the duration of treatment at 8 weeks was relatively short and the dose lower than that assessed by others [9, 10] .
We and others have shown impairment of microvascular endothelial-dependent vasodilation in patients with SSc, as demonstrated using the non-invasive technique of iontophoresis of ACh (endothelial dependent) [12, 19, 20] . We therefore chose this as the primary outcome measure, although it must be recognized that it is not known whether this impairment in ACh-induced microvascular vasodilation is reversible in SSc, and to our knowledge this has not been previously studied before and after statin therapy in SSc. Studies of changes in endothelial-dependent vasodilation in response to statin therapy in other diseases or conditions have given somewhat conflicting results. In an open study of 4 weeks of atorvastatin 10 mg/day in 22 renal transplant patients, endothelial-dependent vasodilation in response to forearm iontophoresis of ACh (but not to post-occlusive hyperaemia) improved post-treatment [21] . An open study of 24 weeks treatment with fluvastatin 40 mg/day in patients with hypercholesterolaemia and peripheral vascular disease reported an improvement in NaNP iontophoresis-induced forearm microvascular vasodilation (with a trend towards improvement in the ACh response) [22] . However, a randomized, double-blind study in non-hyperlipidaemic patients with type 2 diabetes reported no effect from statin therapy on the response to ACh iontophoresis [23] .
Abou-Raya et al. [9] reported improvements in largevessel, endothelium-dependent vasodilation (brachial flow-mediated, measured by ultrasound) in a study of 6 months treatment with atorvastatin in 40 patients with SSc, 20 of whom were randomly selected to receive active treatment (atorvastatin 40 mg/day) and in a later double-blind study in which 56 patients with SSc were randomly selected to receive atorvastatin 40 mg/day for 4 months [10] .
We found no statistically significant changes in capillaroscopic measurements over time. The use of quantitative capillaroscopy to measure structural microvascular change over time is still at a relatively early stage in its development, but we are confident that there were no important changes within the relatively short time frame of the study.
Unlike us, Abou-Raya et al. [9] found that markers of vascular injury (including vWF) and also high-sensitivity CRP fell on active treatment. Their later study of 4 months treatment with atorvastatin 40 mg/day recorded clinical improvement (including in the number of new digital ulcers and Raynaud's VAS) and also improvement in endothelial markers including vWF [10] . In our study, we did not find any effect of atorvastatin on severity of RP nor on levels of vWF. Our patients had longer established disease than those in Abou-Raya et al.'s [10] study, in which mean duration of Raynaud's was 8.0 years and mean disease duration 6.7 years, and our treatment period at 2 months was shorter and the dose of atorvastatin lower.
In conclusion, our study has shown that 8 weeks treatment with atorvastatin 20 mg/day, in patients with well-established SSc and with normal levels of cholesterol, does not improve markers of microvascular endothelial function, structure or damage. However, the large variation in outcome scores means that it is not possible to rule out an effect on the basis of this trial. Possible contributing factors to the lack of observed effects include www.rheumatology.oxfordjournals.org the short duration of therapy and the fact that all patients had well-established disease at the time of inclusion into the study. Given that other investigators have reported beneficial effects, which may derive from the multiple different actions of statins, further research is required including longer term studies and studies including patients with early disease as this subgroup might be more amenable to intervention.
Rheumatology key messages
. Eight weeks treatment with atorvastatin 20 mg/day did not improve dermal microvascular endothelial function in patients with SSc. . Longer term studies are required, including patients with early disease.
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